It remains not entirely accepted that changes in prostanoid metabolism in the blood vessel wall, as well as in whole blood, have a certain influence on vascular responsiveness to vasoactive agents. The aim of the present study is to elucidate whether platelet-derived thromboxane A2 (TxA2) participates in enhancement of vasoconstractile response to a pressor agent. Platelet aggregation was extraluminally induced by application of collagen to autologous platelet rich plasma (PRP), and then the PRP treated with collagen was infused into the perfusion system by means of a small infusion pump. All the prostanoids in the perfusate were assayed radioimmunologically. Infusion into the perfusion system of PRP treated with collagen, as well as that of untreated PRP, apparently caused pronounced enhancement of vasocontractile response to noradrenaline (NA), accompanied by elevations of both the level of TxB2, a stable metabolite of TxA2, and the TxB2/prostaglandin E (PGE)
Introduction
It is well known that blood flow is regulated by neurogenic, humoral, myogenic and structural factors (Uchida & Bohr, 1969) . Total peripheral vascular resistance, related intimately to these factors, seems to be partially influenced by plasma constituents (Moretti & Abraham, 1978 ; Rothhut, 1983 ) and blood corpuscle-derived vasoactive substances (GarciaSzabo, 1988 ; O'Brien et al., 1988) . However, in many reports concerning vascular responsiveness, blood vessel contractility using a normal test solution (Tyrode's solution, Krebs' solution, etc.), containing plasma constituents and/or blood corpuscles has hardly been examined. And so, the results obtained in angiological investigations performed using normal test solutions do not always appear to reflect the genuine blood vessel contractility in the body. Even if an experiment using vascular preparations could be carried out by means of whole blood perfusion, (Cappuccio, 1986 ; Nowak & FitzGerald, 1987 (Michibayashi, 1984 ; Nowak & FitzGerald, 1987 ; Neri Serneri et al., 1990 (Ignarro et al., 1987a ; Ignarro et al., 1987b ), endothelin (Yanagisawa et al., 1988 Salom et al., 1991) , platelet-derived growth factor (Araki et al., 1990 ) and leukotriene (Wittman et al., 1987 ; Hillyard et al., 1991 
